Compounds > 1-cyclopentyl-3-(4-phenoxyphenyl)thiourea
Page last updated: 2024-12-09

1-cyclopentyl-3-(4-phenoxyphenyl)thiourea

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

1-cyclopentyl-3-(4-phenoxyphenyl)thiourea is a chemical compound with the following structure:

**Structure:**

```
/ \\
/ \\
/ \\
/_______\\
| |
C C
| |
|_______|
| |
N N
| |
H S
| |
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |
|_______|
C C
| |

Cross-References

ID SourceID
PubMed CID892293
CHEMBL ID1488377
CHEBI ID111220

Synonyms (11)

Synonym
n-cyclopentyl-n'-(4-phenoxyphenyl)thiourea
smr000198611
MLS000579329
OPREA1_419285
1-cyclopentyl-3-(4-phenoxyphenyl)thiourea
STK143466
CHEBI:111220
AKOS002320380
HMS2548E18
CHEMBL1488377
Q27190834
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
aromatic etherAny ether in which the oxygen is attached to at least one aryl substituent.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (11)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, Beta-lactamaseEscherichia coli K-12Potency3.98110.044717.8581100.0000AID485294
LuciferasePhotinus pyralis (common eastern firefly)Potency26.85450.007215.758889.3584AID588342
glp-1 receptor, partialHomo sapiens (human)Potency28.18380.01846.806014.1254AID624417
TDP1 proteinHomo sapiens (human)Potency23.10930.000811.382244.6684AID686978
P53Homo sapiens (human)Potency14.12540.07319.685831.6228AID504706
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency0.28180.035520.977089.1251AID504332
polyunsaturated fatty acid lipoxygenase ALOX12Homo sapiens (human)Potency14.12541.000012.232631.6228AID1452
nuclear receptor ROR-gamma isoform 1Mus musculus (house mouse)Potency5.01190.00798.23321,122.0200AID2546; AID2551
gemininHomo sapiens (human)Potency23.10930.004611.374133.4983AID624296
survival motor neuron protein isoform dHomo sapiens (human)Potency3.54810.125912.234435.4813AID1458
Guanine nucleotide-binding protein GHomo sapiens (human)Potency8.91251.995325.532750.1187AID624287
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (5)

Processvia Protein(s)Taxonomy
negative regulation of inflammatory response to antigenic stimulusGuanine nucleotide-binding protein GHomo sapiens (human)
renal water homeostasisGuanine nucleotide-binding protein GHomo sapiens (human)
G protein-coupled receptor signaling pathwayGuanine nucleotide-binding protein GHomo sapiens (human)
regulation of insulin secretionGuanine nucleotide-binding protein GHomo sapiens (human)
cellular response to glucagon stimulusGuanine nucleotide-binding protein GHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (2)

Processvia Protein(s)Taxonomy
G protein activityGuanine nucleotide-binding protein GHomo sapiens (human)
adenylate cyclase activator activityGuanine nucleotide-binding protein GHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (1)

Processvia Protein(s)Taxonomy
plasma membraneGuanine nucleotide-binding protein GHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (13)

Assay IDTitleYearJournalArticle
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (5)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (20.00)29.6817
2010's3 (60.00)24.3611
2020's1 (20.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.56

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.56 (24.57)
Research Supply Index1.79 (2.92)
Research Growth Index4.36 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.56)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other5 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
ConditionIndicatedRelationship StrengthStudiesTrials
Innate Inflammatory Response
[description not available]		02.0510
Inflammation
A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.		02.0510